

InspireMD, Inc.  
Form 8-K  
January 27, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 27, 2015

**InspireMD, Inc.**

(Exact name of registrant as specified in its charter)

Delaware	001-35731	26-2123838
(State or other	(Commission File Number)	(IRS Employer
jurisdiction		Identification No.)
of incorporation)		

321 Columbus Avenue

02116

Edgar Filing: InspireMD, Inc. - Form 8-K

Boston, Massachusetts

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (857) 453-6553

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

Attached hereto as Exhibit 99.1 is a PowerPoint presentation that Professor Piotr Musiałek presented on January 27, 2015, at the LINC (Leipzig InterNational Course) meeting in Leipzig, Germany, with respect to the six month follow-up data from its CGuard™ CARENET (CARotid Embolic protection Study using microNET) trial.

The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 8.01 Other Events.**

On January 27, 2015, InspireMD, Inc. (the “Company”) issued a press release announcing that the Company received CE mark approval for its new CGuard RX rapid exchange system for its MicroNet™ covered carotid stent technology and that the six month follow-up data from its CGuard™ CARENET trial were presented at the LINC meeting in Leipzig, Germany on January 27, 2015.

A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

(d)Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	2015 LINC Presentation
99.2	Press release dated January 27, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**inspiremd, inc.**

Date: January 27, 2015 By: /s/ Craig Shore  
Name: Craig Shore  
Title: Chief Financial Officer